Morgan Stanley Purchases 27,160 Shares of Nymox Pharmaceutical Corp (NASDAQ:NYMX)

Morgan Stanley lifted its position in shares of Nymox Pharmaceutical Corp (NASDAQ:NYMX) by 32.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 110,694 shares of the biopharmaceutical company’s stock after buying an additional 27,160 shares during the quarter. Morgan Stanley owned approximately 0.16% of Nymox Pharmaceutical worth $160,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. A.R.T. Advisors LLC bought a new position in shares of Nymox Pharmaceutical during the 2nd quarter worth $28,000. Private Advisor Group LLC bought a new position in shares of Nymox Pharmaceutical during the 2nd quarter worth $55,000. Wedbush Securities Inc. grew its position in shares of Nymox Pharmaceutical by 6.3% during the 2nd quarter. Wedbush Securities Inc. now owns 120,935 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 7,200 shares in the last quarter. Finally, Weiss Asset Management LP bought a new position in shares of Nymox Pharmaceutical during the 2nd quarter worth $72,000. 3.95% of the stock is currently owned by institutional investors and hedge funds.

NYMX opened at $1.81 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.38 and a quick ratio of 5.36. Nymox Pharmaceutical Corp has a 12-month low of $1.25 and a 12-month high of $2.75. The business’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $1.76.

Nymox Pharmaceutical (NASDAQ:NYMX) last issued its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter. Nymox Pharmaceutical had a negative return on equity of 189.25% and a negative net margin of 12,408.26%.

Separately, ValuEngine downgraded Nymox Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, October 25th.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Featured Story: Monthly Dividend Stocks Can Provide Solid Income

Institutional Ownership by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.